Tanaka Y, Hirata S, Kubo S, *et al*. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. *Ann Rheum Dis* 2015;74:389--95. In table [3](#ANNRHEUMDIS2013204016CORR1TB3){ref-type="table"} (B) values of 95% CI were not correct. The corrected table [3](#ANNRHEUMDIS2013204016CORR1TB3){ref-type="table"} (B) is given below.

###### 

\(B\) Multivariate logistic regression analysis

  Items                       Odds    95%CI            Chi-square   p Value
  --------------------------- ------- ---------------- ------------ ----------
  Age (years)                 0.963   0.906 to 1.024   1.441        0.2300
  ADA admin periods (weeks)   0.985   0.959 to 1.011   1.254        0.2629
  DAS28-ESR                   0.143   0.029 to 0.711   5.653        0.0174\*
  RF (U/mL)                   1.012   0.996 to 1.028   2.127        0.1448

Univariate logistic regression analysis was performed using items with p\<0.1 in table 2 to investigate factors related to sustained remission for 1 year after ADA discontinuation. Then, multivariate analyses were conducted using the variables with p\<0.2 in the univariate analysis. Using the DAS28-ESR values which were significant in logistic analysis, ROC analysis was conducted with the response (dependent) variable of if DAS28-ESR \<2.6 (1) or ≥2.6 (0) 1 year after discontinuation of ADA and the explanatory variable of DAS28-ESR at the timing of ADA discontinuation.

\*p\<0.01: Wald test.

ADA, adalimumab; DAS28, disease activity score 28; RF, rheumatoid factor.
